Northern Trust Corp Atai Life Sciences N.V. Transaction History

Northern Trust Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.27 - $2.28 $59,616 - $107,027	-46,942 Reduced 31.86%	100,401 $129,000
Q2 2023 Aug 11, 2023	BUY	$1.44 - $2.19 $18,630 - $28,334	12,938 Added 9.63%	147,343 $253,000
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $20,672 - $47,706	-17,669 Reduced 11.62%	134,405 $243,000
Q4 2022 Feb 13, 2023	BUY	$2.38 - $3.55 $80,436 - $119,979	33,797 Added 28.57%	152,074 $404,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $10,980 - $17,030	3,497 Added 3.05%	118,277 $391,000
Q2 2022 Aug 12, 2022	BUY	$3.03 - $5.32 $147,760 - $259,435	48,766 Added 73.87%	114,780 $417,000
Q1 2022 May 13, 2022	SELL	$4.66 - $7.66 $7,866 - $12,930	-1,688 Reduced 2.49%	66,014 $336,000
Q4 2021 Feb 08, 2022	BUY	$6.82 - $17.8 $93,236 - $243,343	13,671 Added 25.3%	67,702 $516,000
Q3 2021 Nov 15, 2021	BUY	$13.62 - $19.48 $735,902 - $1.05 Million	54,031 New	54,031 $800,000

12.8M

9.2K

118K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $189M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.